Cowen: CBD Market Could Reach $16B By 2025

The U.S. cannabidiol market should expect to see continued gains in the years ahead, according to Cowen.

What Happened 

The CBD market could represent a $16-billion opportunity by 2025, according to a report issued Monday by a team of Cowen analysts.

The findings are based on a roughly 40-percent increase in consumer incidence with the average user spending $640 — or less than $2 per day — each year.

To generate its findings, Cowen convened 11 of its analysts in its consumer, health care, industrials and regulatory teams to analyze the market; 2,500 consumers were surveyed to determine the findings. The report noted a higher than expected amount of CBD consumption.

"We were surprised to see that nearly 7 percent of respondents in January 2019 reported using CBD as a supplement,” the report said. This was the first month of data and findings could fluctuate, Cowen said.

The Cannabis Capital Conference is coming back to Toronto April 17-18!

Hemp — and its non-psychoactive derivative CBD — were federally legalized with the signing of the Farm Bill in January, but CBD-infused food remains illegal in the eyes of the federal government.

Why It's Important

The analysts compared CBD to another craze: JUUL vapes.

“Indeed, to put the 6.9-percent incidence rate in context, that compares to JUUL use of 4.2 percent, and 19.6 percent of consumers that consider themselves a current tobacco user, per our survey.”

Much of Cowen's estimations are conservative, according to the research firm.

This includes a belief that CBD use will grow 10 percent among adults, totaling around 25 million consumers by 2025.

The conservatism extends to the $16-billion forecast itself, the analysts said: "We can envision a scenario where a consumer that uses a CBD tincture or capsule may also be inclined to convert his or her beauty regimen to include CBD (e.g., CBD infused beauty products), and/or use a topical for targeted relief as well."

What's Next

Dissecting the industry a bit more, Cowen said it anticipates health and wellness to lead the market, with nutraceuticals earning $6.4 billion and topicals generating another $4 million. Smaller markets like food, beverages, beauty and vapor are all expected to have sales between $1 billion and $2.5 billion in the same time frame, in the sell-side firm's view.

Related Links: 

OTC Stock Life On Earth Surges Following CBD Beverage Announcement 

Scoop: One Of America's Top Pharmaceutical Drug Directories Includes CBD Products For The First Time Ever 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorCannabisTop StoriesMarketsAnalyst RatingscannabidiolCBDCowenHempmarijuana
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.